NeuroSense Therapeutics Ltd.
NRSN | NASDAQ
$1.99
-$0.14 (-6.57%)
At close: Oct 30, 2026, 4:00 PM ET
$1.99
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 89K | n/a | n/a |
Gross Profit | n/a | n/a | n/a | -89K | n/a | n/a |
Operating Income | -11.09M | -9.9M | -12.05M | -13.55M | -5.59M | -2.89M |
Interest Income | 13K | 2K | 178K | 91K | n/a | 61K |
Pretax Income | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M | -2.83M |
Net Income | -11.13M | -10.21M | -10.11M | -12.34M | -4.04M | -2.83M |
Selling & General & Admin | 4.86M | 4.2M | 4.78M | 7.05M | 2.51M | 393K |
Research & Development | 6.23M | 5.7M | 7.27M | 6.42M | 3.08M | 2.5M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 11.09M | 9.9M | 12.05M | 13.46M | 5.59M | 2.89M |
Interest Expense | n/a | 311K | 550K | 15K | 1.15M | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 11.09M | 9.9M | 12.05M | 13.55M | 5.59M | 2.89M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.27M | 930.1K | 682K | 575.25K | 542.8K | 275.95K |
Shares Outstanding (Diluted) | 1.27M | 930.1K | 682K | 575.25K | 542.8K | 275.95K |
EPS (Basic) | -8.80 | -11 | -16.60 | -21.40 | -4.60 | -10.20 |
EPS (Diluted) | -8.80 | -11 | -16.60 | -21.40 | -4.60 | -10.20 |
EBITDA | -11.11M | -9.88M | -9.64M | -12.23M | -2.88M | -2.83M |
EBIT | -11.13M | -9.9M | -9.66M | -12.32M | -2.89M | -2.83M |
Depreciation & Amortization | 16K | 22K | 21K | 89K | 3K | 3K |
Add to Watchlist
Select watchlists to add or remove NRSN